PR in the Philippines

TOKYO, Japan, September 29, 2025 - (JCN Newswire via SeaPRwire.com) - NEC Corporation (NEC; TSE: 6701) has published the third edition of its report summarizing business risks and opportunities related to natural capital, aligned with the recommendations of the Taskforce on Nature-related Financial Disclosures (TNFD).In creating this report, NEC significantly enhanced the comprehensiveness of site analysis by leveraging the expertise and know-how of its specialized personnel and incorporating it into generative AI and agentic AI. Specifically, NEC analyzed local risks related to water infrastructure at each analysis site—risks that were difficult to grasp using conventional generic tools. Moreover, communication materials were automatically generated and the number of sites subject to detailed analysis were expanded to approximately 2,000 (*1). This enabled dialogue with local stakeholders based on actual conditions. Going forward, NEC plans to further deepen engagement with upstream partners in the value chain.NEC TNFD Report, Third Edition URL: https://www.nec.com/en/global/sustainability/eco/pdf/NEC-tnfd-en.pdfIn recent years, demand for global disclosure of information on sustainability has rapidly intensified. This requires companies to possess specialized knowledge and handle significant workloads. NEC, with the realization of a sustainable society as its Purpose, is actively engaged in this field.Since publishing Japan's first TNFD report in the IT industry in July 2023, NEC has continued its proactive activities, including issuing the second edition of its TNFD report in June 2024 (*2), which reflects the TNFD Final Recommendations v1.0. NEC also contributes to the development of international schemes, participating in activities that include the creation of IT sector guidance for use by the World Economic Forum (*3) and collaborating with TNFD's Nature Data Public Facility (NDPF, (*4)). Insights gained from these experiences are woven into this report. Furthermore, this TNFD report leverages generative AI and agentic AI. Treating NEC itself as "client zero," the company first thoroughly utilizes advanced technologies internally, then applies the resulting know-how and insights to help solve customer challenges. This is used not merely for disclosure purposes, but as a tool for minimizing risks and maximizing opportunities.Benefits of Utilizing Generative AI and Agentic AI Overview of the Third Edition1. Deepening and Expanding Nature-Related Risk Assessment- For approximately 2,000 NEC Group sites and upstream value chain locations, conducting quantitative analysis of water scarcity and flood/storm risks through collaboration with specialized institutions, and enabling water-related local risk analysis using generative AI and Agentic AI.- Visiting sites located in areas requiring attention and engaging in dialogue with local stakeholders (Practicing the Landscape Approach).- Analyzing the impacts of future natural scenarios on business operations using generative AI.- Organizing the hierarchy of upstream value chain segments (mining, material manufacturing, component manufacturing) and developing future investigation strategies.2. Organizing an Opportunity Framework Leveraging NEC's Strengths- As a part of the client zero approach, integrating generative AI and Agentic AI services into consulting services, and visualizing environmental information in enterprise IT systems.- Introducing five themes that generate value for solving environmental challenges through partnerships with other sectors, leveraging NEC's technologies such as trust technologies and material informatics.Going forward, NEC will incorporate in-depth investigations of supply chain risks into its next mid-term environmental plan, the "Eco Action Plan," starting in 2026, and drive its implementation. Furthermore, insights from the generative AI developed this time will be applied to reporting works under sustainability disclosure standards (SSBJ) and responses to external surveys.NEC will take the lead in tackling various challenges to realize data-driven nature-related management. Through its own practical experience, the company will contribute to customers and society by sharing insights gained through consulting and other services.(*1) Conventionally, local risk assessments have required approximately 40 hours per site. By leveraging Agentic AI, simultaneous assessment of multiple sites can be conducted within about one hour. Utilizing Agentic AI is expected to yield efficiency gains equivalent to approximately 80,000 hours compared to conventional methods for assessing local risks across roughly 2,000 sites.(*2) NEC publishes TNFD Report (2nd Edition)https://www.nec.com/en/press/202407/global_20240729_02.html(*3) Nature Positive Transitions: Sectors: Reports compiled by the World Economic Forum in collaboration with Oliver Wyman that outline actions that each sector should take to transition towards a nature-positive economy. NEC is collaborating with other leading global companies to create the IT sector report.(*4) TNFD Nature Data Public Facility https://tnfd.global/enhancing-market-access-to-global-nature-data/About NEC CorporationNEC Corporation has established itself as a leader in the integration of IT and network technologies while promoting the brand statement of "Orchestrating a brighter world." NEC enables businesses and communities to adapt to rapid changes taking place in both society and the market as it provides for the social values of safety, security, fairness and efficiency to promote a more sustainable world where everyone has the chance to reach their full potential. For more information, visit NEC at https://www.nec.com.  Copyright 2025 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

HIROSHIMA, Japan, May 29, 2025 - (JCN Newswire via SeaPRwire.com) - Mazda Motor Corporation's production and sales results for August 2025 are summarized below.I. Production BreakdownAugust 2025Jan - Aug 2025UnitsYoYChange (%)UnitsYoYChange (%)DOMESTIC PRODUCTIONPassenger Vehicles48,903+4.3454,694-7.9Total48,903+4.3454,694-7.9 OVERSEAS PRODUCTIONPassenger Vehicles35,851-8.8290,481-1.9Total35,851-8.8290,481-1.9 GLOBAL PRODUCTIONPassenger Vehicles84,754-1.7745,175-5.7Total84,754-1.7745,175-5.71. Domestic ProductionMazda's domestic production volume in August 2025 increased 4.3% year on year due to increased production of passenger vehicles.[Domestic production of key models in August 2025]CX-5:20,457 units(up 43.9% year on year)MAZDA3:8,537 units(up 10.2%)CX-30:8,040 units(up 29.7%)2. Overseas ProductionMazda's overseas production volume in August 2025 decreased 8.8% year on year due to decreased production of passenger vehicles.[Overseas production of key models in August 2025]CX-50:11,337 units(up 1.7% year on year)CX-30:7,918 units(down 25.1%)MAZDA2:6,624 units(up 6.5%)II. Domestic Sales BreakdownAugust 2025Jan - Aug 2025UnitsYoYChange (%)UnitsYoYChange (%)DOMESTIC SALESPassenger Vehicles9,194+0.097,223+16.7Commercial Vehicles732-7.16,592-2.4 Registration Total7,535+3.380,502+24.4Micro-mini Total2,391-10.923,313-8.1Total9,926-0.5103,815+15.2Mazda's domestic sales volume in August 2025 decreased 0.5% year on year due to decreased sales of commercial vehicles.Mazda's market share was 4.0% (up 0.5 points year on year) in the registered vehicle segment, 2.1% in the micro-mini vehicle segment (down 0.1 points), and the total market share was 3.3% (up 0.3 points).[Domestic sales of key models in August 2025]MAZDA2:1,717 units(down 2.1% year on year)CX-5:1,534 units(down 10.3%)MAZDA3:854 units(up 102.4%)III. Exports BreakdownAugust 2025Jan - Aug 2025UnitsYoYChange (%)UnitsYoYChange (%)EXPORTSPassenger Vehicles45,623-7.6384,138-11.3 North America17,042-15.6190,455+1.1Europe13,856+44.175,562-22.5Oceania3,696+6.335,833-12.9Others11,029-31.582,288-22.3Total45,623-7.6384,138-11.3Mazda's export volume in August 2025 decreased 7.6% year on year due to decreased shipments to regions such as North America.[Exports of key models in August 2025]CX-5:20,645 units(up 10.7% year on year)MAZDA3:7,861 units(down 9.3%)CX-30:7,639 units(up 18.4%)IV. Global Sales BreakdownAugust 2025Jan - Aug 2025UnitsYoYChange (%)UnitsYoYChange (%)GLOBAL SALESDomestic Sales9,926-0.5103,815+15.2 U.S.A38,140-7.6293,494+3.5 China5,707+9.543,636-15.6 Europe7,911-22.7101,771-13.3 Others37,179-9.7304,508+4.6Overseas Sales88,937-9.1743,409-0.0Total98,863-8.3847,224+1.6Mazda's global sales volume in August 2025 decreased 8.3% year on year due to decreased sales in markets such as the USA and Europe.[Global sales of key models in August 2025]CX-5:26,335 units(down 14.7% year on year)CX-30:16,195 units(down 13.3%)Mazda3:11,549 units(down 12.2%)*1 Overseas production figures indicate Mazda-brand units coming off the production line (excluding CKD units).*2 Global production figures represent the total sum of domestic and overseas production volumes.*3 All information in this press release is as of the release date. No updates after that date are reflected.  Copyright 2025 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

KARIYA, JAPAN, September 29, 2025 - (JCN Newswire via SeaPRwire.com) - DENSO CORPORATION (Headquarters: Kariya City, Aichi Prefecture; President: Shinnosuke Hayashi, hereinafter referred to as “DENSO”) and TÜV Rheinland Japan, Ltd. (Headquarters: Yokohama City, Kanagawa Prefecture; President: Kunihiro Okamoto, hereinafter referred to as “TÜV Rheinland Japan”) are pleased to announce that DENSO and TÜV Rheinland Japan have signed a memorandum of understanding in order to realize sustainable manufacturing for industrial products, including batteries, and to promote the Digital Product Passport*1 (hereinafter referred to as “DPP”), which contributes to the efforts.In recent years, there has been a strong demand across entire society for achieving carbon neutrality and transitioning to a circular economy that circulates resources within the economic system, therefore it has been accelerating efforts to create sustainable products. As a part of these efforts, the EU implemented the Ecodesign Regulation*2 in July 2024, introducing a new framework that mandates environmental considerations from the design stage of products. Under this regulation, the introduction of the DPP, which electronically records information such as the manufacturer, materials used, CO2 emissions, and recyclability, is required.Furthermore, from February 2027, under the European Battery Regulation*3, the introduction of the “Battery Passport” for battery products, including automotive and industrial batteries, is scheduled to become mandatory as the first use case of the DPP.To support compliance with these regulations, DENSO is developing an application for the Battery Passport and, in February 2025, became the first Japanese company to obtain EcoPass certification from Catena-X*4.In addition, TÜV Rheinland Japan is a third-party certification body that provides testing, certification, inspection, and evaluation services related to product safety and quality, and always offers the latest evaluation services in various industrial fields.DENSO and TÜV Rheinland Japan have now agreed to comprehensively collaborate as strategic partners on verification and certification services for compliance with the Ecodesign Regulation and the European Battery Regulation, as well as on DPP initiatives.Collaboration DetailsThe two companies will cooperate in the development of DPP and related business services, including the Battery Passport.The two companies will collaborate on regulatory compliance and client support related to the Battery Passport.TÜV Rheinland Japan will provide third-party verification and certification services for DENSO's Battery Passport application.The two companies will jointly create technical documentation related to the Battery Passport for clients.Through extensive collaboration, DENSO and TÜV Rheinland Japan will promote DPP initiatives, including the Battery Passport, and contribute to the realization of a sustainable society.Comments from Each CompanyDENSO CORPORATION, Senior Director, Head of Social Innovation Business Development Function Unit, Mitsuru Kato DENSO is committed to traceability and resource circulation throughout the entire product lifecycle. We are very pleased to have established a strategic partnership with TÜV Rheinland Japan, a third-party certification body with extensive experience and expertise, to promote our initiatives related to DPP, which support these efforts. By combining DENSO’s manufacturing expertise and traceability technologies with TÜV Rheinland Japan’s certification and evaluation capabilities, we aim to provide even more reliable products to stakeholders worldwide.TÜV Rheinland Japan Ltd., President, Kunihiro OkamotoTÜV Rheinland Japan provides various testing, certification, and auditing services in accordance with international standards, and has expanded services to support environmentally conscious business operations and sustainable development in recent years. DENSO possesses advanced technologies in the automotive industry, and we expect that this new partnership will open up new possibilities and promote growth for both companies. Together, we will strive for the realization of a sustainable society.Scene from the signing of the memorandum of understandingFrom left to right: Kunihiro Okamoto, President of TÜV Rheinland Japan,and Mitsuru Kato, Senior Director, Head of Social Innovation Business Development Function Unit, DENSO.*1 Digital Product Passport: A digital certificate that records various information to ensure traceability along the product lifecycle, including the manufacturer, materials used, recyclability, and dismantling methods, as proof of the product's sustainability.*2 Ecodesign Regulation: A comprehensive framework that improves environmental performance standards from the design stage for almost all products introduced to the European market, including durability, recyclability, reparability, and energy efficiency, including the DPP. It came into effect in Europe in July 2024.*3 European Battery Regulation: A regulation that sets unified obligations for the design, material procurement, manufacturing, collection, and recycling of batteries to promote the production and use of sustainable and safe battery products. It came into effect in Europe in August 2023, and the application of each requirement has been gradually starting from February 2024.*4 DENSO the First Company Headquartered in Japan to Acquire EcoPass Certification from Catena-X | Newsroom | News | DENSO Global Website  Copyright 2025 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

Toyota City, Japan, September 29, 2025 - (JCN Newswire via SeaPRwire.com) - Toyota Motor Corporation announces its sales, production, and export results for August 2025, including those for subsidiaries Daihatsu Motor Co., Ltd. and Hino Motors, Ltd.Click here for detailed sales, production, and export results ("Detailed data (Excel)")Toyota Motor Corporation works to develop and manufacture innovative, safe and high-quality products and services that create happiness by providing mobility for all. We believe that true achievement comes from supporting our customers, partners, employees, and the communities in which we operate. Since our founding over 80 years ago in 1937, we have applied our Guiding Principles in pursuit of a safer, greener and more inclusive society. Today, as we transform into a mobility company developing connected, automated, shared and electrified technologies, we also remain true to our Guiding Principles and many of the United Nations' Sustainable Development Goals to help realize an ever-better world, where everyone is free to move.SDGs Initiatives: https://global.toyota/en/sustainability/sdgs/  Copyright 2025 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

TOKYO, Japan, September 29, 2025 - (JCN Newswire via SeaPRwire.com) - Isuzu Motors Limited (Isuzu) and Toyota Motor Corporation (Toyota) announced today an agreement to jointly develop next-generation fuel cell (FC) route buses for commercialization. Production is scheduled to begin in fiscal year 2026 (April 2026-March 2027) at the Utsunomiya Plant (Utsunomiya City, Tochigi Prefecture) of J-Bus, Ltd. (J-Bus), an equal joint venture between Isuzu and Hino Motors, Ltd. (Hino).The vehicle will be based on the flat-floor battery electric route bus platform planned, developed, and designed by Isuzu and manufactured by J-Bus. Isuzu and Hino-who have been collaborating in the bus segment since 2002-launched this platform in fiscal year 2024. It will be combined with an FC system developed by Toyota. As part of their efforts to realize zero-emission vehicles, Isuzu and Toyota are jointly developing the next-generation FC bus, seeking to reduce costs by standardizing BEV and FCEV parts.Expanding the range of carbon neutral options beyond battery electric buses, Isuzu is working to commercialize the next-generation FC route bus as a new technology. Toyota positions hydrogen as an important energy source in the pursuit of carbon neutrality and is advancing various initiatives in producing, transporting, storing, and using hydrogen in collaboration with a wide range of partners across industries. Together, the two companies will work with local governments and businesses in various regions-including those designated by the Ministry of Economy, Trade and Industry in May 2025 as Priority Regions for Promoting the Deployment of Fuel-Cell Commercial Vehicles - to contribute to the steady reduction of CO2 emissions by expanding the use of next-generation FC route buses."Achieving zero, and adding new value beyond it"As part of efforts to pass our beautiful "Home Planet" to the next generation, Toyota has identified and is helping to solve issues faced by individuals and overall society, which Toyota calls "Achieving Zero," hoping to help reduce the negative impacts caused by these issues to people and the environment to zero. Additionally, Toyota is also looking "Beyond Zero" to create and provide greater value by continuing to diligently seek ways to improve lives and society for the future.About Beyond Zero: https://global.toyota/en/mobility/beyond-zero/Toyota Motor Corporation works to develop and manufacture innovative, safe and high-quality products and services that create happiness by providing mobility for all. We believe that true achievement comes from supporting our customers, partners, employees, and the communities in which we operate. Since our founding over 80 years ago in 1937, we have applied our Guiding Principles in pursuit of a safer, greener and more inclusive society. Today, as we transform into a mobility company developing connected, automated, shared and electrified technologies, we also remain true to our Guiding Principles and many of the United Nations' Sustainable Development Goals to help realize an ever-better world, where everyone is free to move.SDGs Initiatives: https://global.toyota/en/sustainability/sdgs/  Copyright 2025 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

DUBAI, Sept 29, 2025 - (ACN Newswire via SeaPRwire.com) - 31 CONCEPT (31C), a leading UAE-based cybersecurity innovator, today announced the strategic acquisition of Xynthor AI Software Inc., a Canadian company pioneering AI-native Data Loss Prevention (DLP) solutions. This acquisition strengthens 31C's commitment to advancing Deep Packet Intelligence (DPI), corporate security, and data sovereignty in an AI-centric world.31 Concept & XynthorBy integrating Xynthor's "DLP for AI Era" with 31C's DPI expertise, the combined platform will deliver the most comprehensive AI-aware security solution available. This move addresses the growing need for security systems capable of handling modern AI-driven workflows.Why It MattersThe rise of generative AI tools such as ChatGPT and Claude has outpaced the capabilities of traditional DLP systems, which were built for structured data and static rules. High-profile incidents, including the accidental leakage of proprietary source code by Samsung engineers using ChatGPT, highlight the urgent need for AI-specific safeguards.Misha Hanin, CEO of 31C, emphasized: "The convergence of AI and cybersecurity is the most significant paradigm shift our industry has ever seen. Traditional methods cannot manage the dynamic, context-aware data flows of today's AI environments. Through this acquisition, we are pioneering an entirely new category of AI-native security solutions."Xynthor's Breakthrough TechnologyXynthor brings several unique differentiators:AI Data Guardian: Prevents sensitive information from leaving the organization using NLP-driven detection.Air-Gapped Architecture: Keeps analysis inside the client's environment, ensuring privacy and compliance.Context-Aware Intelligence: Reduces false positives through AI-driven classification and behavioral analysis.Private LLM Protection: Enables safe use of internal large language models without external exposure.Seamless Integration: Works with existing infrastructure while supporting regulations like HIPAA and GDPR.Comprehensive AI-Era PlatformThe integrated platform enhances DPI with real-time policy management, adaptive threat detection, and behavioral analytics. It also streamlines compliance with GDPR, HIPAA, PCI DSS, and upcoming AI governance standards.Boris Heismann, CTO of 31C, stated: "We're not only responding to current demands but anticipating tomorrow's challenges. Combining DPI with AI-native DLP creates a future-ready security platform."Strategic ImpactThe global cost of data breaches averages over $4 million per incident, and AI-driven risks are only increasing. By uniting DPI and AI-native DLP, 31C positions itself as a global leader capable of addressing these critical challenges.This acquisition aligns with 31C's growth strategy, including performance-based incentives tied to Xynthor's product success. Both companies will continue to operate from the UAE and Canada, combining their strengths to accelerate innovation and market expansion.About 31CFounded in the UAE, 31C is a cybersecurity company specializing in Deep Packet Intelligence, corporate security, and data sovereignty. Its innovative approach makes it a trusted partner for enterprises, governments, and regulators worldwide.About Xynthor AIBased in Canada, Xynthor AI develops AI-native security platforms designed to protect organizations using generative AI, ensuring both safety and compliance in the AI era.For more information about 31C's Next Gen DPI solutions, visit https://31c.io.Contact InformationMisha HaninCEOmisha.hanin@31c.ioSOURCE: 31 Concept Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Kawasaki and Tsukuba, Japan, September 29, 2025 - (JCN Newswire via SeaPRwire.com) - Fujitsu Limited and the Global Research and Development Center for Business by Quantum-AI technology (G-QuAT) at the National Institute of Advanced Industrial Science and Technology (AIST) today announced the signing of a collaboration agreement to strengthen international industrial competitiveness in quantum technology. The agreement, signed on September 26, 2025, aims to enhance cooperation between the two organizations, thereby boosting Japan's standing globally in this sector.As part of the agreement, Fujitsu and G-QuAT will leverage their combined resources, including quantum computer-related technologies, manufacturing and evaluation facilities, and will promote research and development and personnel exchange. In this way, the partnership aims to foster international collaboration and research cooperation, ultimately contributing to sustainable economic growth.Scaling up quantum computers requires the integration of diverse elemental technologies and the comprehensive verification and optimization of the entire quantum computer system. To address this challenge, the two organizations will promote research cooperation, including the development of supporting environments and demonstration of technologies necessary for large-scale superconducting quantum computers, maximizing the use of G-QuAT's facilities and its hub function for international collaboration. Through this initiative, the partners aim to establish the superiority of Japan's quantum computing technology, including that of component manufacturers, and actively promote it globally to foster expansion into the international market.Photo of MASU Kazuya, G-QuAT Director (right) and Vivek Mahajan, Corporate Executive Officer, Corporate Vice President, CTO, in charge of System Platform, Fujitsu Limited (left) signing ceremonyAbout FujitsuFujitsu’s purpose is to make the world more sustainable by building trust in society through innovation. As the digital transformation partner of choice for customers around the globe, our 113,000 employees work to resolve some of the greatest challenges facing humanity. Our range of services and solutions draw on five key technologies: AI, Computing, Networks, Data & Security, and Converging Technologies, which we bring together to deliver sustainability transformation. Fujitsu Limited (TSE:6702) reported consolidated revenues of 3.6 trillion yen (US$23 billion) for the fiscal year ended March 31, 2025 and remains the top digital services company in Japan by market share. Find out more: global.fujitsuAbout National Institute of Advanced Industrial Science and Technology (AIST) The National Institute of Advanced Industrial Science and Technology (AIST), one of the largest public research organizations in Japan, focuses on the creation and practical realization of technologies useful to Japanese industry and society, and on “bridging” the gap between innovative technological seeds and commercialization. Global Research and Development Center for Business by Quantum-AI technology (G-QuAT), established in 2023, promotes the social implementation of advanced convergence computational technology and aims to build a global business ecosystem to solve economic and social issues, create new markets, and pioneer aftermarkets from the benefits. Find out more: G-QuATPress ContactsFujitsu LimitedInquiriesGlobal Research and Development Center for Business by Quantum-AI technology (G-QuAT)E-mail: M-G-QuAT-plan-ml*aist.go.jp (Please convert "*" to "@".) Copyright 2025 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

HONG KONG, Sep 29, 2025 - 28 September, The world's first 9,300 CEU methanol dual-fuel Pure Car and Truck Carrier (PCTC), "CM HONG KONG", celebrated its maiden voyage with a ceremony in Tsing Yi, Hong Kong. Vice-chairperson of the National Committee of the Chinese People's Political Consultative Conference, Leung Chun-ying, Chief Secretary for Administration of the HKSAR, Chan Kwok-kei, Deputy Director of the Liaison Office of the Central People's Government in the HKSAR, Qi Bin, and Chairman of China Merchants Group Limited, Miao Jianmin, etc. attended the ceremony, with Executive Vice President of China Merchants Group Limited, Deng Renjie, as the master of ceremonies.During the event, a commemorative plaque was presented to the ship's captain. Guests toured the vessel's bridge, crew quarters, and innovative methanol dual-fuel system, witnessing its advancements in low-carbon technology and operational efficiency.Built for China Merchants Energy Shipping (CMES), "CM HONG KONG" is the first large-scale car carrier powered by a methanol dual-fuel system, enabling seamless switching between conventional fuel and methanol. Compliant with IMO Tier III emission standards, it achieves over 70% emissions reduction when using green methanol. The ship, measuring 219.9 meters long and 37.7 meters wide, has a design capacity of 9,300 CEUs, with an actual capacity of up to 9,492 CEUs. Its 78,416-square-meter loading area, equivalent to 11 football fields, features 13 decks, including three adjustable lift decks and three tailored for hydrogen fuel cell vehicles. Dual stern and side ramps boost loading/unloading efficiency by 30%. Safety is enhanced with 156 CCTV cameras and thermal imaging infrared sensors across all decks."CM HONG KONG" embarked on its inaugural China-to-Europe route, unloading vehicles in Hong Kong before heading to Europe. Leveraging Hong Kong's free port status, CMES aims to advance the "green fuel trade + port services" model, fostering economic growth, attracting international vessels for green fuel bunkering, and strengthening Hong Kong's role as a global green maritime hub.Vice-chairperson of the National Committee of the Chinese People's Political Consultative Conference, Leung Chun-ying, delivered a speech at the ceremony.Chief Secretary for Administration of the HKSAR, Chan Kwok-kei, delivered a speech at the ceremony.Chairman of China Merchants Group Limited, Miao Jianmin, delivered a speech at the ceremony. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

SINGAPORE, Sept 29, 2025 - (ACN Newswire via SeaPRwire.com) - The future arrived today in Singapore as the World Quantum Summit 2025 (WQS) — themed “Quantum Unboxed: Extending the Reach of AI” — concluded at the Sheraton Towers Singapore with a full house attendance filling the ballroom to capacity. The overwhelming turnoutunderscored the growing global appetite for practical quantum solutions that extend the power of artificial intelligence and accelerate its real-world impact.This year’s summit was not a standalone event but the culmination of a three-day intensive journey into the future of computing and intelligence. On 23–24 September, participants took part in a sold-out Executive Workshop on Quantum and AI, which built foundational understanding of quantum principles, emerging architectures, and integration strategies. The final day brought it all together, showcasing how those concepts are now being deployed in industry — from real-world applications to large-scale investment strategies.Unlike traditional conferences focused solely on research or theory, WQS 2025 brought together the entire ecosystem driving quantum innovation forward. The summit featured practitioners representing different quantum approaches, policy makers, venture investors, academics, corporates, researchers, and ecosystem partners — all converging under one roof to chart the path from lab breakthroughs to industry-scale adoption. On the exhibition floor, leading players such as ST Engineering, QBoson, and TM Research & Development showcased quantum - enhanced solutions in optimisation, secure computing, and AI acceleration. Meanwhile, Gold Capital Network Partners — IMGT and IWC Management — hosted curated sessions connecting founders and investors to accelerate funding into quantum ventures poised for growth.A key highlight was the line-up of 19 world-class speakers, each offering cutting-edge insights into how quantum is transforming the AI landscape. Among them were Assoc. Prof. Mile Gu, Deputy Director of the Nanyang Quantum Hub at Nanyang Technological University; Jeremy Woo, Senior Technical Advisor at D-Wave System; Deepak Waghmare, CTO (APJC) of Dell Technologies; Ujjwal Kumar, Principal Architect, Office of the CTO at Microsoft Asia; Dr. Simon See, Senior Director and Global Head of the NVIDIA AI Technology Center; Bruno Aznar Martinez, R&D Software Developer at Keysight Technologies; Raghunath Koduvayur, CEO of RAQS Quantum; Gao Qi, Algorithm Director at QBoson; Ken Chew, CEO and Partner of IWC Management; and Tony Gu, General Partner at NGC Ventures. They were joined by Ong Yongcheng of Insignia Ventures, Dr. Amelia Tan of ST Engineering, Eric Lee of Deloitte Southeast Asia, Atsushi Sugiura of Oxford Quantum Circuits, Hidetoshi Matsumura of Fujitsu Limited, Ray Han of SAP, Duleesha Kulasooriya of Deloitte, Manisha Sharma Kohli of Google, and Simon Lawrie of AWS.Throughout the summit, a clear narrative emerged: quantum computing has moved beyond theory into strategic deployment, offering a powerful multiplier for AI. Industry leaders showcased case studies where quantum-enhanced AI is already delivering breakthrough results —  from accelerating molecular simulations and optimising financial portfolios to solving supply chainchallenges previously considered intractable. Discussions highlighted how enterprises are integrating quantum capabilities directly into their AI workflows, achieving dramatic improvements in processing power, speed, efficiency, and cost-to-insight.The summit also reflected the shifting investment landscape. As quantum technologies mature, institutional and venture capital investors are moving rapidly to back companies with commercially viable products and near-term revenue potential. “Quantum is no longer the future —  it’s today’s most powerful strategic edge and already seeing some real applications,” said Ken Chew, CEO of IWC Management. “The confluence of quantum and AI and their cross-synergies are powerful and those who integrate it into their AI stack early will potentially define the competitive landscape of the next decade.”By the close of the event, one message was clear: quantum will not replace AI — it will supercharge it. With practitioners, investors, policymakers, and researchers now aligned on the urgency of adoption, the era of practical quantum applications is no longer a distant vision — it is here, and it is redefining howindustries think about computation, intelligence, and innovation.The World Quantum Summit has firmly established itself as Asia’s premier platform for quantum commercialisation, bridging science, industry, and capital to accelerate real-world adoption. With its unique focus on applications over abstraction and its ability to convene the full quantum ecosystem, WQS is not just a conference — it is a catalyst for the next wave of technological transformation.Media Contact:Eric KhooConference Director, TPGI Pte Ltderic.khoo@pinnaclegroup.global+65 8383 2480 Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Hong Kong Department of Health accepts NDA for dorzagliatin, the world’s first approved glucokinase activator (GKA).Builds on China approval and strong Phase III and real-world clinical results showing durable glucose control and safety.Positions Hong Kong as a strategic gateway for Hua Medicine’s global expansion into Southeast Asia and beyond.SHANGHAI, Sept 29, 2025 - (ACN Newswire via SeaPRwire.com) - Hua Medicine (“the Company”, HKEX: 2552) announced that the Department of Health of the Hong Kong Special Administrative Region of China accepted a New Drug Application (NDA) for dorzagliatin, the world’s first glucokinase activator (GKA) approved for the treatment of Type 2 diabetes (T2D).The acceptance of the NDA marks an important milestone in Hua Medicine’s strategy to expand beyond China, bringing its innovative, disease-modifying treatment to more patients across Asia and ultimately to global markets.With more than half a million people living with diabetes in Hong Kong and nearly 240 million across Asia, the NDA represents a significant step toward addressing one of the region’s most urgent health challenges.A first-in-class therapy with global potentialDorzagliatin was approved for marketing by the China National Medical Products Administration (NMPA) in September 2022 for two indications, both to improve blood glucose control for T2D patients, 1) It can be used as mono-treatment for drug-naïve T2D patients, as first-line treatment, 2) When metformin hydrochloride alone has poor blood glucose control, it can be used in combination with metformin hydrochloride. Unlike conventional drugs that manage symptoms, dorzagliatin targets the root cause of blood sugar dysregulation by repairing the function of glucokinase (GK), the body’s glucose sensor. By restoring glucose sensitivity, dorzagliatin helps maintain blood sugar balance and supports long-term disease management.Results from two Phase III registration trials in China demonstrated that dorzagliatin significantly and sustainably lowered HbA1c levels, improved pancreatic β-cell function, and reduced insulin resistance, all while showing strong safety and tolerability.  Findings are being further validated in ongoing real-world studies, of which some interim analysis and data were presented at the 2025 American Diabetes Association (ADA) Scientific Sessions.Strategic gateway to new marketsHong Kong has established a comprehensive, community-based system for diabetes management and serves as a medical and financial hub for the region. Research findings from the Hong Kong Diabetes and Obesity Research Institute at The Chinese University of Hong Kong indicate that the implementation of a community-based public-private collaboration model for diabetes management provided significant benefits to the community. The advanced experience in Hong Kong is of great significance for improving the quality of life of diabetes patients, controlling the progression of the disease, and reducing the burden on the healthcare system. Once approved in Hong Kong, it will also provide clinical application of dorzagliation for the personalized management of diabetes.According to Hong Kong's former new drug approval mechanism, applicants were required to submit to the authority new drug registration certificates issued by the drug regulatory agencies of two or more recognized countries, as well as other specified relevant documents, in order to support the approval and marketing of the product. Under the newly established "1+" mechanism, after meeting requirements such as local clinical data support and having the applicable scope of the new drug endorsed by local experts, an applicant only needs to submit the approval from one (instead of the original two) reference drug regulatory authority to apply for registration of the new drug in Hong Kong. This mechanism initially applied to new drugs for the treatment of serious or rare diseases, and has been extended to all new drugs since 2024.Under the leadership of Ms. Beili Cao, Vice President of Department of Corporate Operation and Great Bay Development, Hua Medicine has conducted sufficient and in-depth communications with local clinical experts and regulatory authorities in Hong Kong, and became an early pioneer of this mechanism. The Company filed its application for registration of dorzagliatin in Hong Kong at the end of July, and the application was officially accepted by the end of September.Dr. Li Chen, Founder and Chief Executive Officer of Hua Medicine, said: “Acceptance of dorzagliatin’s NDA in Hong Kong is not only recognition of its clinical value but also a pivotal step in Hua Medicine’s international journey. Hong Kong’s unique position as a regional healthcare leader and financial hub makes it the ideal gateway for expanding dorzagliatin’s reach into Southeast Asia and beyond. We are committed to working with local doctors and partners in Hong Kong to explore dorzagliatin’s potential in both treatment and prevention of prediabetes and early-stage diabetes, ensuring more patients worldwide can benefit from this breakthrough therapy.”Dorzagliatin: A transformative T2D treatmentDorzagliatin was approved in September 2022 in China, and it was included in the country’s National Reimbursement Drug List (NRDL) as of January 1, 2024.Dorzagliatin can be used alone as a first-line therapy for newly diagnosed patients, or together with metformin when blood sugar control is inadequate. Unlike many other approved oral antidiabetes drugs, no dose adjustment is required for patients with kidney impairment. It works by repairing the body’s glucose sensor, glucokinase (GK), restoring glucose sensitivity and long-term blood sugar balance. It acts across key organs—stimulating insulin secretion in the pancreas, boosting GLP-1 secretion in the gut, and regulating glycogen in the liver. This multi-target approach addresses the root cause of Type 2 diabetes, not just its symptoms.The NDA application in Hong Kong is based on the results of two Phase III registration clinical studies conducted in China evaluating the use of dorzagliatin monotherapy and in combination with metformin for the treatment of patients with Type 2 diabetes. Two studies have shown that for two categories of T2D patients—those newly diagnosed and not yet on medication, and those who have failed to respond adequately to metformin therapy— dorzagliatin can sustainably and effectively lower patients' HbA1c levels by repairing defects in the glucose sensor function of GK, significantly reduce postprandial two-hour blood glucose levels (2h-PPG), achieve high glycemic control rates without hypoglycemia, demonstrate good safety and tolerability, and continuously improve β-cell function and reduce insulin resistance.Forward-Looking StatementsThis document contains statements regarding Hua Medicine’s future expectations, plans, and prospects for the Company and its products. These forward-looking statements pertain only to events or information as of the date they are made and may change due to future developments. Unless required by law, we are not obligated to update or publicly revise any forward-looking statements or unexpected events after the date of such statements, regardless of new information, future events, or other circumstances. Please read this document carefully and understand that our actual future performance or results may differ materially from expectations due to various risks, uncertainties, or other legal requirements.About Hua MedicineHua Medicine (The “Company”) is an innovative drug development and commercialization company based in Shanghai, China, with companies in the United States and Hong Kong. Hua Medicine focuses on developing novel therapies for patients with unmet medical needs worldwide. Based on global resources, Hua Medicine teams up with global high-calibre people to develop breakthrough technologies and products, which contribute to innovation in diabetes care. Hua Medicine's cornerstone product HuaTangNing (dorzagliatin tablets), targets the glucose sensor glucokinase, restores glucose sensitivity in T2D patients, and stabilizes imbalances in blood glucose levels in patients. HuaTangNing was approved by the National Medical Products Administration (NMPA) of China on September 30th, 2022. It can be used alone or in combination with metformin for adult T2D patients. For patients with chronic kidney disease (CKD), no dose adjustment is required. It is an oral hypoglycemic drug that can be used for patients with Type 2 diabetes with renal function impairment.For more informationHua MedicineWebsite: www.huamedicine.comInvestorsWebsite: ir@huamedicine.comMediaWebsite: pr@huamedicine.com Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

TOKYO, Sep 29, 2025 - (ACN Newswire via SeaPRwire.com) – Quantum Solutions Co., Ltd. (Tokyo Stock Exchange Code: 2338.T, “Quantum”) announced its strategic financing initiative on September 26 to issue 44 million shares to a blue-chip investor mix of three heavyweight institutions, providing the necessary permanent capital and network access to position Quantum as a potential frontrunner in the world of  Ethereum (ETH) listed strategies and a showcase standout in the Tokyo stock market.For Japanese investors, this represents another significant commitment by leading US capital, following Warren Buffett’s investment in Japan’s five major trading companies. For international investors, it signals that Tokyo’s stock market is an increasingly attractive destination for global capital, welcoming new opportunities for “smart money”.Dream Team of Global Capital Aligns for Quantum, International Demand for Japanese Equities Continues to GrowQuantum’s investor line-up is a market stunner in the emerging field of crypto-linked equities. Susquehanna International Group (SIG), investing via CVI Investments, holds the capital firepower to accelerate Quantum’s ETH accumulation and expand its balance sheet for upcoming fundraising rounds. With a portfolio that includes early investments in ByteDance and Strategy Inc. (NASDAQ: MSTR), SIG is a Tokyo Stock Exchange participant, offering the robust capital infrastructure that analysts consider essential for a successful Digital Asset Treasury (DAT).Cathie Wood affirms her position as the world’s leading investor in crypto-linked equities with ARK Invest’s first direct foray into APAC-listed opportunities. In the US market, ARK has a track record for identifying category leaders such as ETH Treasury Bitmine Immersion Technologies (NYSE: BMNR) and cryptocurrency exchange Coinbase (NASDAQ: COIN). By adding Quantum, Wood extends her expertise to the Tokyo market, bringing visibility to Quantum in front of the global investing audience as the region’s most promising ETH Treasury initiative.The third participant is Hong Kong-based Integrated Asset Management (IAM), led by Mr. TC Yam. As the majority shareholder of Forbes Media, IAM’s cross-sector presence in international finance and media resources bolsters Quantum’s capital depth and reputational standing. Like ARK, IAM makes its first public investment in the Tokyo stock market, signaling growing confidence among global institutional investors in Japan's equity market.The fundraise utilizes convertible bonds and both floating and fixed strike price warrants for a total issuance of approximately 44 million shares, nearly doubling the company’s existing share capital. None of the instruments are priced at a discount, a rarity for DAT fundraises, suggesting that the incoming investors are targeting long-term growth prospects. As of market closing on September 26, the nominal value of the financing round comes to over JPY 26 billion (approx. USD 180 million), with the first tranche valued at JPY 22.1 billion (approx. USD 150 million).First ETH Treasury in Japan — A Differentiated Strategy Offering Long-Term Returns on EquityAccording to research reports by leading investment banks, the key determinants of success for listed Digital Asset strategies are robust access to capital and a team with operational blockchain expertise. Through this fundraising initiative, Quantum taps into fresh sources of capital and aligns with investors of strong reputation, prompting market expectations of long-term backing.Quantum CEO Francis B. Zhou is no newcomer to the Digital Asset industry, as one of the first institutional investors and operators in the blockchain space. In 2018, Zhou acquired the world’s second largest ETH mining facility, based in Jokkmokk, Sweden. Zhou maintains investments in early stage blockchain projects alongside film and IP holdings in his venture investment portfolio, and brings a network of experienced blockchain operators, including Head of Crypto Strategy Donny Chi.Proceeds from Quantum’s financing initiative will be used to accumulate ETH. Although BTC has demonstrated adoption as a store-of-value, ETH is the foundational asset for blockchain applications, enabling companies like Quantum to explore attractive yield-generating opportunities to drive a blend of organic and inorganic growth for the company’s core treasury and balance sheet.The appeal of yield-bearing strategies is supported by data from the US market, which indicates that listed ETH Treasuries trade at a price-to-book multiple of 7.72x, more than 3 times higher than that of listed BTC Treasuries. More remarkably, the price-to-book of ETH Treasuries is trending upwards, increasing by over 20% within the trading month of September, demonstrating that the market expectations continue to strengthen for listed ETH Treasuries as it relates to long-term returns on equity.Zhou and the Quantum Solutions team have a history of exploring growth frontiers, consequently developing industry traction in AI computing, GPU hosting, and IP gaming. This positions the company to pursue unique opportunities beyond overcrowded sectors in Real World Asset (RWA) space to potentially generate more attractive returns.With the fundraise, Quantum’s notional price-to-book multiple is estimated to be less than 30% of the market median. Assuming that the company can reach its fair value, the structure of the fundraise allows the company to rapidly accelerate its capital accumulation to reach the target of 100,000 ETH within the near term, positioning Quantum among the leading ETH Treasury companies globally.Growth Driven Policies in Japan Encourage Prospects for Long-Term Shareholder ValueConsistent government support for the blockchain industry and increasing clarity in regulations are ushering in a more investor-friendly market for Digital Assets in Japan. Whereas the US market already has ETH Treasury companies such as Bitmine (NASDAQ: BMNR) and SharpLink Gaming (NASDAQ: SBET) achieving significant market cap growth as capital market highlights, Japan lacks a similar listed benchmark. Quantum Solutions’ entry fills this gap, opening a new chapter as "Japan’s first”, and creating conditions for capital inflow and renewed market participation.This financing round, nominally valued at approximately USD 180 million, is a landmark in both the Japanese stock market as well as the crypto-linked equities space. Through the combined endorsement of SIG, ARK, and IAM, Quantum not only secures funding but also international validation under a capital structure optimized to maximize long-term shareholder value. High-profile deals of this caliber further Tokyo as an emerging destination for savvy investors. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Sept 29, 2025 - (ACN Newswire via SeaPRwire.com) - Tianli International Holdings Limited (“Tianli International”) and Shenzhen Yidatong Group recently held a formal signing ceremony in Hong Kong to launch their strategic partnership. The agreement, signed at 3:00 PM on September 25th, marks the official start of a high-end international school project in the heart of Laos’s National Administrative Center.This collaboration represents far more than a commercial alliance. It is a key milestone in Tianli International’s dual strategic priorities—“Education AI” and “China International Education Going Global”—and a concrete step in response to China’s Belt and Road Education Initiative and the national blueprint China Education Modernization 2035, which calls for “a new era of educational openness.”Under the agreement, the partners will jointly develop a world-class international education complex featuring two flagship schools:Premier British Boarding School, offering a complete UK curriculum and authentic boarding traditions to nurture the next generation of global leaders from Laos and neighboring countries.Lida Chinese International School, centered on China’s national curriculum, this school will provide both general and academic Chinese tracks, establish a direct pathway to China’s top universities, and promote two-way student exchange programs.The signing ceremony drew congratulations from the China Association for Non-Government Education, which praised the project as a pioneering example of Chinese private education expanding abroad. Guests and witnesses attended from China, Laos, France, Malaysia, Gambia, and other countries.Dr. Luo Shi, Chairman and President of Tianli International, stated that the partnership is both a pivotal milestone in the group’s global strategy and a major advance in its “Education AI + China International Education Going Global” initiative. Looking ahead, the two partners plan to explore innovations in smart-campus infrastructure and AI-driven teaching, delivering high-quality, diversified education options to Southeast Asia and the wider world.Media ContactCompany: Tianli Education (HK ) LimitedContact Person: Dr. Brown FengZhaoEmail: zhaofeng@tianlieducation.com Website: https://www.tianlieducation.com/en/about/index.html Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

TOKYO and CAMBRIDGE, Mass., Sept. 29, 2025 - (JCN Newswire via SeaPRwire.com) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that humanized anti- soluble aggregated amyloid-beta (Aβ) monoclonal antibody “LEQEMBI®” (generic name: lecanemab) has been approved for once every four weeks intravenous (IV) maintenance dosing by the National Medical Products Administration (NMPA) in China.In January 2024, LEQEMBI was approved for the treatment of Alzheimer's disease (AD) in patients with mild cognitive impairment (MCI) or mild dementia stage of disease (collectively referred to as early AD) in China. After 18 months of a dosing regimen of 10 mg/kg once every two weeks during initiation phase, a transition to the maintenance dosing regimen of 10 mg/kg once every four weeks may be considered or the regimen of 10 mg/kg once every two weeks may be continued.AD is a progressive, relentless disease characterized by formation of protein deposits known as plaques made of amyloid-beta aggregates and neurofibrillary tangles made of tau protein in the brains of people living with AD. It is caused by a continuous underlying neurotoxic process that begins before amyloid plaque accumulation and continues after plaque removal.1,2,3,4 The data show that Aβ protofibrils* and tau tangles play roles in the neurodegeneration process,2,3 and LEQEMBI is the only approved therapy that fights AD in two ways – targeting both amyloid plaque and protofibrils, which can impact tau downstream.Eisai estimates that, as of 2024, there were 17 million patients with MCI or mild dementia due to AD in China in 2024, which is expected to increase with the aging of the population. Eisai serves as the lead for lecanemab’s development and regulatory submissions globally with Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority. In China, Eisai distributes the product and conducts information provision activities through specialized Medical Representatives.* Protofibrils are believed to contribute to the brain injury that occurs with AD and are considered to be the most toxic form of Aβ, having a primary role in the cognitive decline associated with this progressive, debilitating condition.1 Protofibrils cause injury to neurons in the brain, which in turn, can negatively impact cognitive function via multiple mechanisms, not only increasing the development of insoluble Aβ plaques but also increasing direct damage to brain cell membranes and the connections that transmit signals between nerve cells or nerve cells and other cells. It is believed the reduction of protofibrils may prevent the progression of AD by reducing damage to neurons in the brain and cognitive dysfunction.4MEDIA CONTACTSEisai Co., Ltd.Public Relations Department+81 (0)3-3817-5120Eisai Europe, Ltd.(UK, Europe, Australia, New Zealand and Russia)EMEA Communications Department+44 (0) 7739 600678EMEA-comms@eisai.netEisai Inc. (U.S.)Libby Holman+ 1-201-753-1945Libby_Holman@eisai.comBiogen Inc.Madeleine Shin+ 1-781-464-3260public.affairs@biogen.comINVESTOR CONTACTSEisai Co., Ltd.Investor Relations Department+81 (0) 3-3817-5122Biogen Inc.Tim Power+ 1-781-464-2442IR@biogen.com About LEQEMBI (generic name: lecanemab)Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ). Protofibrils are believed to contribute to the brain injury that occurs with AD and are considered to be the most toxic form of Aβ, having aprimary role in the cognitive decline associated with this progressive, debilitating condition. Lecanemab has been approved in 50 countries and is under regulatory review in 10 countries. Following the initial phase with treatment every two weeks for 18 months, intravenous (IV) maintenance dosing with treatment every four weeks was approved in China, the U.S. and others, and applications have been filed in 5 countries and regions.LEQEMBI's approvals in these countries were based on Phase 3 data from Eisai's, global Clarity AD clinical trial, in which it met its primary endpoint and all key secondary endpoints with statistically significant results. The primary endpoint was the global cognitive and functional scale, Clinical Dementia Rating Sum of Boxes (CDR-SB).1,5 The U.S. FDA approved Eisai’s Biologics License Application (BLA) for subcutaneous maintenance dosing with LEQEMBI IQLIK in August 2025. In September 2025, the rolling sBLA application to the U.S. FDA for the subcutaneous initiation dosing with LEQEMBI IQLIK was also initiated.Since July 2020 the Phase 3 clinical study (AHEAD 3-45) for individuals with preclinical AD, meaning they are clinically normal and have intermediate or elevated levels of amyloid in their brains, is ongoing. AHEAD 3-45 is conducted as a public-private partnership between the Alzheimer's Clinical Trial Consortium that provides the infrastructure for academic clinical trials in AD and related dementias in the U.S, funded by the National Institute on Aging, part of the National Institutes of Health, Eisai and Biogen. Since January 2022, the Tau NexGen clinical study for Dominantly Inherited AD (DIAD), that is conducted by Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by Washington University School of Medicine in St. Louis, is ongoing and includes lecanemab as the backbone anti-amyloid therapy.About the Collaboration between Eisai and Biogen for ADEisai and Biogen have been collaborating on the joint development and commercialization of AD treatments since 2014. Eisai serves as the lead of lecanemab development and regulatory submissions globally with Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority.About the Collaboration between Eisai and BioArctic for ADSince 2005, Eisai and BioArctic have had a long-term collaboration regarding the development and commercialization of AD treatments. Eisai obtained the global rights to study, develop, manufacture and market lecanemab for the treatment of AD pursuant to an agreement with BioArctic in December 2007. The development and commercialization agreement on the antibody lecanemab back-up was signed in May 2015.About Eisai Co., Ltd.Eisai's Corporate Concept is "to give first thought to patients and people in the daily living domain, and to increase the benefits that health care provides." Under this Concept (also known as human health care (hhc) Concept), we aim to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities. With a global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to create and deliver innovative products to target diseases with high unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology.In addition, we demonstrate our commitment to the elimination of neglected tropical diseases(NTDs), which is a target (3.3) of the United Nations Sustainable Development Goals (SDGs), by working on various activities together with global partners.For more information about Eisai, please visit www.eisai.com (for global headquarters: Eisai. Co., Ltd.), us.eisai.com (for U.S. headquarters: Eisai, Inc.) or www.eisai.eu (for Europe, Middle East, Africa, Russia, Australia and New Zealand headquarters: Eisai Europe Ltd.), and connect with us on X (global and U.S), LinkedIn (for global, U.S. and EMEA) and Facebook (global).About BiogenFounded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patients’ lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth.For more information, visit: https://www.eisai.com/news/2025/pdf/enews202567pdf.pdf  Copyright 2025 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com